Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potency Evaluations of Recombinant Botulinum Neurotoxin A1 Mutants Designed to Reduce Toxicity.

International journal of molecular sciences - 17 Aug 2024

Viravathana Polrit, Tepp William H, Bradshaw Marite, Przedpelski Amanda, Barbieri Joseph T, Pellett Sabine

Abstract excerpt

Recombinant mutant holotoxin BoNTs (rBoNTs) are being evaluated as possible vaccines against botulism. Previously, several rBoNTs containing 2-3 amino acid mutations in the light chain (LC) showed significant decreases in toxicity (2.5-million-fold-12.5-million-fold) versus wild-type BoNT/A1, leading to their current exclusion from the Federal Select Agent list. In this study, we added four additional mutations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Substitution
Share to Escherichia coli

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Recombinant Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 39201641
DOI: 10.3390/ijms25168955
PMCID: PMC11355004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potency Evaluations of Recombinant Botulinum Neurotoxin A1 Mutants Designed to Reduce Toxicity.PMID 39201641Read ↗

New Engineered-Chimeric Botulinum Neurotoxin Mutant Acts as an Effective Bivalent Vaccine Against Botulinum Neurotoxin Serotype A and E.Semantic proximity Read ↗

Rational design of botulinum neurotoxin A1 mutants with improved oxidative stability.Semantic proximity Read ↗

The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A SubtypesSemantic proximity Read ↗

Characterization of a membrane binding loop leads to engineering botulinum neurotoxin B with improved therapeutic efficacy.Semantic proximity Read ↗

Probing the structure and function of the protease domain of botulinum neurotoxins using single-domain antibodiesSemantic proximity Read ↗

Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic ApplicationsSemantic proximity Read ↗

Structural Insights into Rational Design of Single-Domain Antibody-Based Antitoxins against Botulinum NeurotoxinsSemantic proximity Read ↗

Challenges in searching for therapeutics against Botulinum NeurotoxinsSemantic proximity Read ↗

A Novel High-Potency Tetanus Vaccine.Semantic proximity Read ↗

Expression and biochemical characterization of light chains of Botulinum neurotoxin subtypes F5 and F7.Semantic proximity Read ↗

A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic.Semantic proximity Read ↗

Light Chain Diversity among the Botulinum NeurotoxinsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.